Carsten Thiel’s Contribution to the Pharmaceutical Industry

Carsten Thiel is a pharmaceutical expert who has improved patient care with his reforms in the medical field. He specializes in biotechnology and has launched several medicinal products, which include Neulasta, Prolia, and Strensiq. Carsten was born and raised in Berlin. He was an exemplary student who excelled in his studies, especially in Chemistry. After high school, Carsten Thiel moved to the UK to join the University of Bristol. Carsten studied Organic Chemistry and later specialized in biochemistry. Carsten has a Ph.D. from the Max Planck Institute for Biophysical Chemistry.

Carsten Thiel first job was at Hoffman la-Roche, where he was the Communications and Product Manager. Thiel quickly rose within the company due to his expertise and knowledge of biotechnology.

Throughout his career, Carsten Thiel has showcased excellent leadership skills and in-depth knowledge of the pharmaceutical industry. Carsten has held several leadership positions within the industry, which helped propel his career. He has skillfully improved customer service and gained peoples’ trust along the way. Once Carsten’s career as an international leader was stable, he was given a project to launch Xenical, a weight loss product. Carsten had not dealt with marketing products to masses directly before. He usually dealt with medical providers, marketing fine chemicals, and vitamins to them. He, therefore, put all his energy into this particular project and came up with a way to effectively communicate with clients concerning Xenical.

Carsten Thiel was aware that many companies make huge promises to clients when launching their products, earning them a lot of customers. However, not many people want to stick to the lifestyle that is necessary to maintain weight loss, and the products end up having no effects. The sales begin to decline from this point, and Carsten Thiel did not want the same for Xenical. He chose a method that would appeal to customers, and he was successful in the end.

Carsten Thiel’s: Twitter.